Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10510
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 505–516 of 10,510 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT04390399
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

NCT07260877
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
Interventions
VENT-03, Placebo
Drug
Lead sponsor
Ventus Therapeutics U.S., Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The PorchLight Project

NCT05550727
View directory record Official record
Conditions
Memory Loss, Alzheimer Disease, Dementia
Interventions
PorchLight
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting No phase listed Observational

A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas

NCT02104310
View directory record Official record
Conditions
Malignant Glioma
Interventions
Fluorine-18-L-dihydroxyphenylalanine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Phase 3 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

NCT01575548
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
579
States / cities
Fairbanks, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 355 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

NCT06064071
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Disease
Interventions
Nordlys SWT IPL, Meibomian Gland Expression (MGX), Sham Nordlys SWT IPL
Device · Procedure
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Petosemtamab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
36
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
BMS-986446, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 80 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
119
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Not applicable Interventional

LLLT to Reduce Low Back Pain

NCT06007976
View directory record Official record
Conditions
Low Back Pain
Interventions
Erchonia® Trident
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

NCT05621317
View directory record Official record
Conditions
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions
PVX-108, Placebo
Biological
Lead sponsor
Aravax Pty Ltd
Industry
Eligibility
4 Years to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 2:32 AM EST